Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 654 across all filing types
Latest filing 2021-11-30 Share Issue/Capital Cha…
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Vitrolife slutför förvärvet av Igenomix och genomför en apportemission
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated November 30, 2021, announcing that Vitrolife has completed the acquisition of Igenomix and executed a share issue (apportemission) to finance it. It details the completion of the transaction, the resulting increase in the number of shares, and a delay in the next financial report (bokslutskommunikén). The core subject is a significant corporate action involving financing (share issue) and acquisition completion. This fits best under 'Capital/Financing Update' (CAP) as it explicitly discusses the share issue (apportemission) and the resulting capital structure change, which is a primary component of financing activities. While it relates to an acquisition (TAR), the focus here is heavily on the financing mechanism used to complete it and the resulting share count change.
2021-11-30 Swedish
Vitrolife completes the acquisition of Igenomix and carries out a non-cash consideration issue
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled as a 'Press Release' dated November 30, 2021, announcing the completion of an acquisition (Vitrolife acquires Igenomix) and a related non-cash consideration share issue. This involves changes to the capital structure (issuance of 17,251,312 new shares) and affects the total number of shares. While it touches upon financing/capital structure (CAP) and management changes (Board member appointment), the core event described is a significant transaction involving the issuance of new shares as consideration for an acquisition. This aligns most closely with the 'Share Issue/Capital Change' definition (SHA). It is not a formal regulatory filing like a 10-K, nor is it a simple dividend announcement or earnings release. Since it details the issuance of new shares as consideration, SHA is the most specific fit over the broader CAP category.
2021-11-30 English
Vitrolife offentliggör prospekt för upptagande av aktier på Nasdaq Stockholm med anledning av apportemission
Capital/Financing Update Classification · 95% confidence The document text is explicitly titled 'Prospekt' (Prospectus in Swedish) and details the approval by the Swedish Financial Supervisory Authority ('Finansinspektionen') under EU Prospectus Regulation (EU) 2017/1129. It concerns the listing of newly issued shares in connection with an acquisition (apportemission). A prospectus is a mandatory disclosure document required for public offerings or listing of securities. While it contains financial information, its primary function is to serve as the comprehensive legal and financial disclosure document for a security offering/listing, which aligns best with the regulatory disclosure requirements often associated with a registration statement or offering document. Given the options, 'CAP' (Capital/Financing Update) is relevant due to the share issuance, but 'TAR' (M&A Activity) is also relevant due to the acquisition. However, the document's structure, regulatory context (Prospectus Regulation), and purpose (listing shares) strongly indicate a document related to raising capital or listing securities. In many regulatory frameworks, a prospectus for a listing or offering is a distinct, comprehensive document. Since there isn't a specific 'Prospectus' code, we must choose the closest fit. The document is fundamentally about a capital action (share issuance for acquisition). 'CAP' covers financing activities. 'TAR' covers M&A. Since the document is the formal disclosure required for the listing resulting from the M&A, and it is a comprehensive disclosure document, it is most closely related to the capital raising/listing aspect. However, the term 'Prospekt' is a specific type of offering document. Given the context of a major transaction involving share issuance and listing, 'CAP' (Capital/Financing Update) is a strong candidate, but 'TAR' (M&A Activity) is also highly relevant as the trigger. Since the document is the formal disclosure for the listing resulting from the acquisition, and it is a comprehensive disclosure document, it is most closely related to the capital raising/listing aspect. If we consider the structure and regulatory nature, it is a formal offering document. In the absence of a specific 'Prospectus' code, and noting the focus on the issuance of shares ('nyemitterade aktier') and the associated transaction, 'CAP' (Capital/Financing Update) is the most appropriate category covering the financing aspect of the transaction described in the prospectus.
2021-11-26 Swedish
Vitrolife publishes prospectus in connection with the admission to trading on Nasdaq Stockholm due to non-cash issue
Capital/Financing Update Classification · 95% confidence The document text is explicitly titled 'Prospekt' (Prospectus in Swedish) and details the approval by the Swedish Financial Supervisory Authority ('Finansinspektionen') under EU Prospectus Regulation (EU) 2017/1129. It concerns the listing of newly issued shares in connection with an acquisition (apportemission). A prospectus is a mandatory disclosure document required for public offerings or listing of securities. While it contains financial information, its primary function is to serve as the comprehensive legal and financial disclosure document for a security offering/listing, which aligns best with the regulatory disclosure requirements often associated with a registration statement or offering document. Given the options, 'CAP' (Capital/Financing Update) is relevant due to the share issuance, but 'TAR' (M&A Activity) is also relevant due to the acquisition. However, the document's structure, regulatory context (Prospectus Regulation), and purpose (listing shares) strongly indicate a document related to raising capital or listing securities. In many regulatory frameworks, a prospectus for a listing or offering is a distinct, comprehensive document. Since there isn't a specific 'Prospectus' code, we must choose the closest fit. The document is fundamentally about a capital action (share issuance for acquisition). 'CAP' covers financing activities. 'TAR' covers M&A. Since the document is the formal disclosure required for the listing resulting from the M&A, and it is a comprehensive disclosure document, it is most closely related to the capital raising/listing aspect. However, the term 'Prospekt' is a specific type of offering document. Given the context of a major transaction involving share issuance and listing, 'CAP' (Capital/Financing Update) is a strong candidate, but 'TAR' (M&A Activity) is also highly relevant as the trigger. Since the document is the formal disclosure for the listing resulting from the acquisition, and it is a comprehensive disclosure document, it is most closely related to the capital raising/listing aspect. If we consider the structure and regulatory nature, it is a formal offering document. In the absence of a specific 'Prospectus' code, and noting the focus on the issuance of shares ('nyemitterade aktier') and the associated transaction, 'CAP' (Capital/Financing Update) is the most appropriate category covering the financing aspect of the transaction described in the prospectus.
2021-11-26 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'delårsrapport' (interim report) for Vitrolife AB covering the period January-September 2021. It contains comprehensive financial statements, key performance indicators (KPIs), management commentary, and segment analysis. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2021
2021-10-29 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'interim report january-september 2021' and contains comprehensive financial statements, segment analysis, CEO comments, and key performance indicators for the specified period. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. 9M 2021
2021-10-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.